Press release
The US FDA Gives Shanton Fast Track Status in the Refractory Gout Program
Refractory Gout
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72657
As the burden of gout rises due to aging populations, obesity, and comorbidities, demand for novel biologics, advanced urate-lowering agents, and personalized treatment strategies is expanding. By 2034, the refractory gout market is expected to see robust growth, driven by increasing disease awareness, new drug approvals, and stronger research pipelines.
Market Overview
The global refractory gout market was valued at USD 1.3 billion in 2024 and is projected to reach USD 4.4 billion by 2034, growing at a CAGR of 13% during the forecast period.
Key Highlights:
• Market Size 2024: USD 1.3 billion
• Forecast 2034: USD 4.4 billion
• CAGR (2024-2034): 13%
• Growth Drivers: Rising prevalence of gout, unmet therapeutic needs, and innovation in biologics and small molecules.
• Challenges: High treatment costs, safety concerns with biologics, and limited patient adherence.
• Leading Players: Horizon Therapeutics (Amgen), Takeda Pharmaceutical, Novartis, AstraZeneca, Selecta Biosciences, Sobi (Swedish Orphan Biovitrum), and Jiangsu Hengrui Pharmaceuticals.
The market is shifting from conventional therapies toward biologic and precision medicine approaches, with strong emphasis on long-term disease modification.
Segmentation Analysis
By Drug Class:
• Biologics (e.g., pegloticase, IL-1 inhibitors)
• Xanthine oxidase inhibitors (next-generation agents)
• Uricosuric agents
• Anti-inflammatory therapies
• Pipeline drugs (gene therapies, dual-mechanism drugs)
By Route of Administration:
• Intravenous
• Subcutaneous
• Oral
By Patient Type:
• Chronic refractory gout
• Severe tophaceous gout
• Patients with comorbidities (renal, cardiovascular)
By End-User:
• Hospitals & specialty clinics
• Rheumatology centers
• Academic & research institutes
• Home-based care (biologic injections)
Summary:
Biologics remain the most effective treatment option for refractory gout today, but emerging oral agents and dual-mechanism drugs are expected to broaden treatment choices over the next decade.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72657/refractory-gout-market
Regional Analysis
North America
• Largest market due to advanced healthcare infrastructure, high prevalence of gout, and early adoption of biologics.
• The U.S. dominates with FDA-approved therapies such as pegloticase (Krystexxa).
Europe
• Significant growth in Germany, UK, and France, supported by rare disease funding and broader access to biologics.
• EMA approvals are expanding treatment availability across EU nations.
Asia-Pacific
• Fastest-growing region, led by China, Japan, South Korea, and India.
• Increasing prevalence of gout linked to dietary changes and aging populations.
• Expansion of biologic approvals and clinical trials accelerates adoption.
Middle East & Africa
• Early adoption in GCC countries with investments in specialty care.
• Limited access to biologics in low-resource settings.
Latin America
• Brazil and Mexico showing rising demand, with local partnerships for biologic distribution.
Summary:
North America leads, but Asia-Pacific is expected to record the fastest CAGR (14%+), becoming a major hub for refractory gout treatment by 2034.
Market Dynamics
Key Growth Drivers:
• Increasing number of patients resistant to conventional urate-lowering therapies.
• Expanding biologic pipeline targeting IL-1 and novel inflammatory pathways.
• Growing patient advocacy and awareness of refractory gout.
• Favorable orphan and rare disease drug designations supporting R&D.
Key Challenges:
• High cost of biologics limits accessibility.
• Adherence issues due to long treatment duration.
• Safety concerns with immunosuppressive therapies.
Latest Trends:
• Development of long-acting biologics to reduce dosing frequency.
• Rising use of precision medicine approaches with biomarker-guided treatment.
• Combination therapy strategies (biologics + urate-lowering agents).
• Emerging research into gene therapy and CRISPR-based solutions.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72657
Competitor Analysis
Major Players in the Refractory Gout Market:
• Horizon Therapeutics (Amgen) - Market leader with Krystexxa (pegloticase).
• Takeda Pharmaceutical - Active in urate-lowering therapies.
• Novartis AG - Developing IL-1 inhibitors and biologic therapies.
• AstraZeneca - Innovating next-generation urate-lowering agents.
• Selecta Biosciences - Advancing immune tolerance therapies in refractory gout.
• Sobi (Swedish Orphan Biovitrum) - Expanding biologic portfolio for rare inflammatory disorders.
• Jiangsu Hengrui Pharmaceuticals - Emerging Chinese player in biologics.
Competitive Summary:
The market is dominated by biologic innovators, with Horizon's Krystexxa leading current revenues. However, new biologics, oral agents, and gene-based approaches in clinical pipelines are expected to intensify competition. Partnerships between biotech firms and large pharma are accelerating development timelines.
Conclusion
The Refractory Gout Market is projected to grow from USD 1.3 billion in 2024 to USD 4.4 billion by 2034, at a CAGR of 13%. With biologics setting new standards of care and next-generation therapies on the horizon, the market is positioned for strong long-term growth.
Key Takeaways:
• Market to grow at 13% CAGR (2024-2034).
• Biologics remain the backbone, with pegloticase leading today.
• North America leads, but Asia-Pacific will be the fastest-growing market.
• Competition centers on pipeline innovation, combination strategies, and affordability.
• Long-term opportunities lie in gene therapies, dual-mechanism drugs, and precision medicine approaches.
As refractory gout therapies move toward curative and disease-modifying solutions, the market is set to improve patient outcomes and reduce the burden of this debilitating condition worldwide.
This report is also available in the following languages : Japanese (難治性痛風市場), Korean (난치성 통풍 시장), Chinese (难治性痛风市场), French (Marché de la goutte réfractaire), German (Markt für feuerfeste Gicht), and Italian (Mercato della gotta refrattaria), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72657/refractory-gout-market#request-a-sample
Our More Reports:
CRISPR Gene Editing in Infectious Diseases Market
https://exactitudeconsultancy.com/reports/73646/crispr-gene-editing-in-infectious-diseases-market
Parkinson's Disease in 68 Market
https://exactitudeconsultancy.com/reports/73647/parkinson-s-disease-in-68-market
Respiratory Syncytial Virus Prophylaxis Market
https://exactitudeconsultancy.com/reports/73648/respiratory-syncytial-virus-prophylaxis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The US FDA Gives Shanton Fast Track Status in the Refractory Gout Program here
News-ID: 4201666 • Views: …
More Releases from Exactitude Consultancy
Changing Methods for Taste Masking: Enhancing Patient Compliance and Product Inn …
Introduction
The pharmaceutical and nutraceutical industries are witnessing a growing demand for solutions that improve the palatability of drugs and supplements. For patients, especially children, the elderly, and individuals requiring long-term medication, the unpleasant taste of active pharmaceutical ingredients (APIs) remains a major barrier to compliance. This is where the taste masking services market plays a crucial role.
Taste masking involves the use of specialized technologies and formulations to reduce or eliminate…
Neutra Corp. will establish a new clinical research site management organization …
The global Site Management Organization (SMO) Market is becoming increasingly vital in the clinical research ecosystem, supporting pharmaceutical, biotechnology, and medical device companies in conducting efficient and compliant clinical trials. SMOs provide critical services such as site selection, patient recruitment, regulatory compliance, data management, and site staff training.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72659
With the rising complexity of clinical trials, growing demand for patient-centric approaches, and expansion…
Tr1 Treg Treatment to Be Assessed in a Crohn's Disease Trial
The global Treg Therapy Market is rapidly gaining momentum as regulatory T-cell (Treg) therapies emerge as a transformative approach in immunology. Tregs are a specialized subset of T-cells that maintain immune tolerance and homeostasis, preventing the body from attacking its own tissues. Harnessing these cells offers a promising strategy to treat autoimmune diseases, organ transplant rejection, and chronic inflammatory conditions.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72661
With advancements…
Oral Oncolytics Leukemia Market to Reach USD 24.7 Billion by 2034, Growing at 9. …
Introduction
Leukemia remains one of the most challenging hematological malignancies, with millions of patients worldwide requiring lifelong monitoring and treatment. Traditionally, chemotherapy and injectable biologics dominated the therapeutic landscape, but the advent of oral oncolytics has dramatically changed how leukemia is managed. These targeted therapies, often in the form of small-molecule inhibitors, offer patients the ability to receive effective treatment in a more convenient and less invasive manner compared to hospital-administered…
More Releases for Gout
Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions.
Download…
Chronic Gout Market Massive Growth opportunity Ahead
Introduction
Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia…
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many…
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary
The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032.
Gout Therapeutics Market Introduction
The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often…
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/371311/gout-drugs
Market…
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
